Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma

Trial Profile

Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2019

At a glance

  • Drugs Mogamulizumab (Primary) ; Vorinostat
  • Indications Cutaneous T-cell lymphoma; Mycosis fungoides; Sezary syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms MAVORIC
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 04 Jun 2019 Results of a post-hoc analysis assessing time to next treatment (TTNT) to explore the patient clinical experience presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 03 Jun 2019 Results presented in a Kyowa Hakko Kirin Media Release.
    • 31 May 2019 Results of post-hoc analysis published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top